D
David Sterling
Researcher at University of Colorado Boulder
Publications - 43
Citations - 1588
David Sterling is an academic researcher from University of Colorado Boulder. The author has contributed to research in topics: Tuberculosis & Biomarker discovery. The author has an hindex of 16, co-authored 41 publications receiving 1274 citations. Previous affiliations of David Sterling include University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients With Stable Coronary Heart Disease
Peter Ganz,Peter Ganz,Bettina Heidecker,Bettina Heidecker,Kristian Hveem,Christian Jonasson,Shintaro Kato,Mark R. Segal,David Sterling,Stephen A. Williams +9 more
TL;DR: Among patients with stable CHD, a risk score based on 9 proteins performed better than the refit Framingham secondary event risk score in predicting cardiovascular events, but still provided only modest discriminative accuracy.
Journal ArticleDOI
Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy
Yetrib Hathout,Edward N. Brody,Paula R. Clemens,Paula R. Clemens,Linda H. Cripe,Robert Kirk DeLisle,Pat Furlong,Heather Gordish-Dressman,Lauren P. Hache,Erik K Henricson,Eric P. Hoffman,Yvonne M. Kobayashi,Angela Lorts,Jean K. Mah,Craig M. McDonald,Bob Mehler,Sally K. Nelson,Malti Nikrad,Britta Singer,Fintan Steele,David Sterling,H. Lee Sweeney,Steve C.R. Williams,Larry Gold +23 more
TL;DR: A proteomics approach was described to determine serum levels of 1,125 proteins in 93 DMD patients and 45 controls and identified 44 biomarkers that differed significantly between patients and controls, demonstrating both the utility of this unbiased biomarker discovery approach and suggesting potential new diagnostic and therapeutic avenues for ameliorating the burden of DMD and, it is hoped, other rare and devastating diseases.
Journal ArticleDOI
Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease.
Thomas J. Scriba,Adam Penn-Nicholson,Smitha Shankar,Thomas Hraha,Ethan G. Thompson,David Sterling,Elisa Nemes,Fatoumatta Darboe,Sara Suliman,Lynn M. Amon,Hassan Mahomed,Mzwandile Erasmus,Wendy Whatney,John L. Johnson,W. Henry Boom,Mark Hatherill,Joe Valvo,Mary Ann De Groote,Urs A. Ochsner,Alan Aderem,Willem A. Hanekom,Daniel E. Zak +21 more
TL;DR: A timeline to the different immunological stages of disease progression which comprise sequential inflammatory dynamics and immune alterations that precede disease manifestations and diagnosis of tuberculosis disease is provided.
Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy.
Yetrib Hathout,Edward N. Brody,Paula R. Clemens,Linda H. Cripe,Robert Kirk DeLisle,Pat Furlong,Heather Gordish Dressman,Lauren P. Hache,Erik K Henricson,Eric P. Hoffman,Yvonne M. Kobayashi,Angela Lorts,Jean K. Mah,Craig M. McDonald,Bob Mehler,Sally K. Nelson,Malti Nikrad,Britta Singer,Fintan Steele,David Sterling,H. Lee Sweeney,Steve C.R. Williams,Larry Gold +22 more
Journal ArticleDOI
Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment.
Mary Ann De Groote,Payam Nahid,Leah G. Jarlsberg,John L. Johnson,Marc H Weiner,Grace Muzanyi,Nebojsa Janjic,David Sterling,Urs A. Ochsner +8 more
TL;DR: In this paper, the authors applied a highly multiplexed proteomic technology (SOMAscan, SomaLogic, Inc, Boulder, CO) to understand changes in proteins from paired serum samples at enrollment and after 8 weeks of TB treatment from 39 patients with pulmonary TB from Kampala, Uganda enrolled in the Center for Disease Control and Prevention's Tuberculosis Trials Consortium (TBTC) Study 29.